. Author manuscript; available in PMC: 2019 Apr 1.

Published in final edited form as: Cancer. 2018 Jan 16;124(7):1374–1382. doi: 10.1002/cncr.31218

Table 2.

Hematological Toxicities

Table 2. Hematologic Toxicities (Max Grade per Patient)
Cycle 1 (DLT period: 0–21 days)

	Dose 0				Dose 1				Dose 2				Dose 2A
	20 mg po BID day 1–12				40 mg po BID day 1–12				80 mg po BID day 1–12				80 mg po BID day 1–21
Hematologic Toxicity	G2	G3	G4		G2	G3	G4		G2	G3	G4		G2	G3	G4
Leukopenia					1				2					2	1
Neutropenia	1				1				1					1	2^*
Lymphopenia														2	1
Anemia	1								2				2	2
Thrombocytopenia	1												1		2^*
DLTs		0				0				0				2

Cycle 2 and beyond

	Dose 0				Dose 1				Dose 2				Dose 2A
Hematologic Toxicity	G2	G3	G4	G5	G2	G3	G4	G5	G2	G3	G4	G5	G2	G3	G4	G5
Leukopenia	3					2			1	4			1	2	1
Neutropenia	1		1			2			1	3	2		1	1	2
Lymphopenia		1				1				3				4
Anemia	1	2			1	1				4			2	2
Thrombocytopenia		1	2			1	1		1	2	3		2		1
Febrile Neutropenia															1
Acute Leukemia												1^**

Abbreviations: G, toxicity grade (according to Common Terminology Criteria for Adverse Events version 4).

2 patients experienced both G4 neutropenia and thrombocytopenia.

^**

1 patient experienced acute myeloid leukemia